Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Gardado en:
Autoren: | , , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | inglés |
Publicado: |
Philipps-Universität Marburg
2023
|
Schlagworte: | |
Acceso en liña: | Texto completo PDF |
Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
Sexa o primeiro en deixar un comentario!